 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Press Release New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With MidazolamJune 23, 2008 On June 23, 2008, FDA approved a new Aptivus (tipranavir) oral solution (100 mg/mL). The product label has been updated to include dosing recommendations for pediatric patients 2-18 years of age. In addition, information regarding oral and parenterally administered midazolam was updated in the Contraindication and Drug Interactions section. Please see the attached pdf file for specific pediatric labeling information and for updated information about midazolam.  This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
|
|
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
